A tumour-promoting role of Th9 cells in hepatocellular carcinoma through CCL20 and STAT3 pathways

Clinical and Experimental Pharmacology and Physiology

Volumn 44, Issue 2, 2017, Pages 213-221

  Tan, Hongwu ^a   Wang, Shuyun ^a   Zhao, Ludong ^a  

^a LINYI PEOPLE'S HOSPITAL   (China)

Author keywords

CCL20; hepatocellular carcinoma; STAT3; Th9 cells

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR5; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; STAT3 PROTEIN; CCL20 PROTEIN, HUMAN; IL9 PROTEIN, HUMAN; INTERLEUKIN 9; STAT3 PROTEIN, HUMAN;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE FREE SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; LIVER CELL CARCINOMA; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TH9 CELL; TUMOR PROMOTION; ADULT; AGED; BLOOD; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; CELL CULTURE; FEMALE; FLOW CYTOMETRY; IMMUNOLOGY; LIVER NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELLS, CULTURED; CHEMOKINE CCL20; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-9; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTE SUBSETS;

EID: 85010380292     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12689     Document Type: Article

References (31)

1. Xu C, Zhou W, Wang Y, Qiao L. Hepatitis B virus-induced hepatocellular carcinoma. Cancer Lett. 2014;345:216–22.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.
3. Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene. 2006;25:3823–33.
4. Fu J, Zhang Z, Zhou L, et al. Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology. 2013;58:139–49.
5. Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007;132:2328–39.
6. Flecken T, Schmidt N, Hild S, et al. Immunodominance and functional alterations of tumour-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology. 2014;59:1415–26.
7. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565–70.
8. Sachdeva M, Chawla YK, Arora SK. Immunology of hepatocellular carcinoma. World J Hepatol. 2015;7:2080–90.
9. Végran F, Apetoh L, Ghiringhelli F. Th9 cells: a novel CD4 T-cell subset in the immune war against cancer. Cancer Res. 2015;75:475–9.
10. Purwar R, Schlapbach C, Xiao S, et al. Robust tumour immunity to melanoma mediated by interleukin-9–producing T cells. Nat Med. 2012;18:1248–53.
11. Lu Y, Hong S, Li H, et al. Th9 cells promote antitumour immune responses in vivo. J Clin Invest. 2012;122:4160–71.
12. Lv X, Wang X. The role of interleukin-9 in lymphoma. Leuk Lymphoma. 2013;54:1367–72.
13. Schmitt E, Bopp T, Dougan M, et al. Amazing IL-9: revealing a new function for an “old” cytokine. J Clin Invest. 2012;122:3857–9.
14. Hou K-Z, Fu Z-Q, Gong H. Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition. World J Gastroenterol. 2015;21:475–83.
15. Ding X, Wang K, Wang H, et al. High expression of CCL20 is associated with poor prognosis in patients with hepatocellular carcinoma after curative resection. J Gastrointest Surg. 2012;16:828–36.
16. Meares GP, Ma X, Qin H, Benveniste EN. Regulation of CCL20 expression in astrocytes by IL-6 and IL-17. Glia. 2012;60:771–81.
17. Wong MT, Ye JJ, Alonso MN, et al. Regulation of human Th9 differentiation by type I interferons and IL-21. Immunol Cell Biol. 2010;88:624–31.
18. Schmitt E, Germann T, Goedert S, et al. IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-beta and IL-4, and is inhibited by IFN-gamma. J Immunol. 1994;153:3989–96.
19. Zhao L, Xia J, Wang X, Xu F. Transcriptional regulation of CCL20 expression. Microbes Infect. 2014;16:864–70.
20. Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol. 2006;80:1197–213.
21. Giannelli G, Mazzocca A, Fransvea E, Lahn M, Antonaci S. Inhibiting TGF-β signaling in hepatocellular carcinoma. Biochim Biophys Acta. 2011;1815:214–23.
22. Senturk S, Mumcuoglu M, Gursoy-Yuzugullu O, Cingoz B, Akcali KC, Ozturk M. Transforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumour growth. Hepatology. 2010;52:966–74.
23. Yamasaki A, Saleh A, Koussih L, Muro S, Halayko AJ, Gounni AS. IL-9 induces CCL11 expression via STAT3 signalling in human airway smooth muscle cells. PLoS ONE. 2010;5:e9178.
24. Zhou Y, Sonobe Y, Akahori T, et al. IL-9 promotes Th17 cell migration into the central nervous system via CC chemokine ligand-20 produced by astrocytes. J Immunol. 2011;186:4415–21.
25. Boni C, Fisicaro P, Valdatta C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007;81:4215–25.
26. Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis. 2007;11:797–816.
27. Protzer U, Maini MK, Knolle PA. Living in the liver: hepatic infections. Nat Rev Immunol. 2012;12:201–13.
28. Hu L, Lau SH, Tzang C-H, Wen J-M, Wang W, Xie D, et al. Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene. 2004;23:298–302.
29. Morin PJ. Beta-catenin signaling and cancer. BioEssays. 1999;21:1021–30.
30. Li W, Tan D, Zhang Z, Liang JJ, Brown RE. Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma. Oncol Rep. 2008;20:713–9.
31. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9:265–73.